PRESS RELEASE: VaxEquity Announces Expansion at Cambridge Science Park and of its Senior Team

Appoints Directors of Alliance Management and Finance
May 2022
back

Cambridge, England, 13 May 2022 – VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) platform, today announces its expansion to the Cambridge Science Park.

The company also announces the appointments of Rob Barber as Senior Director, Alliance Management and Conor Woolfson as Finance Director.

Rob Barber, PhD joins from Mundipharma International, where he was responsible for a global portfolio of in-licensed and out-licensed commercial and late-stage development alliances. His previous roles have covered all stages of the drug lifecycle and have included senior positions at biotech and pharmaceutical companies Oxford Biomedica, Novartis, and Shire. Rob has a BA (Hons) from Oxford University, a PhD from the University of Cambridge, and completed his post-doc studies at the Johns Hopkins University School of Medicine.

Conor Woolfson joins from IXICO plc., where he provided finance related support to large pharma and biotech companies across all phases of clinical research. He brings extensive experience across a broad range of UK and US businesses. Conor has a BEng in Mechanical Engineering from University College Dublin and is qualified as a Chartered Accountant.

Michael Watson, Executive Chairman of VaxEquity, said, “I am delighted that Rob and Conor have joined us, to help propel us to the next stage in our development. Rob’s alliance management skills will be invaluable for supporting a pipeline of assets from our flagship partnership with AstraZeneca. As Finance Director, Conor will provide strategic leadership to the company's finance and corporate functions with an immediate focus on building a sound business platform to support and sustain long term growth. I am also delighted that we are expanding our footprint at the prestigious Cambridge Science Park given the benefits that come with being immersed in this world class life sciences ecosystem and being near to our partners AstraZeneca.”

The company will have around 2,000 sq ft of lab space on the UK’s Cambridge Science Park and joins a community of around 6,000 people working in over 100 companies across technology, life sciences and high value manufacturing.

Media contacts

Michael Watson (VaxEquity)

mike.watson@vaxequity.com

Katja Stout (Scius Communications)

katja@sciuscommunications.com

Daniel Gooch (Scius Communications)

daniel@sciuscommunications.com

About VaxEquity

VaxEquity is a UK biotechnology company developing next generation self-amplifying RNA and mRNA therapeutics and vaccines. Our proprietary RNA platform is designed to modulate the innate immune response to enable higher and longer protein expression allowing lower doses and expanding the potential of RNA for therapeutics as well as vaccines.

VaxEquity was founded in 2020 by Imperial College London’s Professor Robin Shattock, and specialist life sciences investor Morningside, and is led by a world class team who are RNA pioneers. The Company is based in Cambridge, UK, and is collaborating with AstraZeneca to progress its platform across multiple disease areas.


To learn more about VaxEquity please visit www.vaxequity.com and follow our LinkedIn.

Get in touch

Thank you for your message

We have recieved your message and will get back to your shortly.